Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.51 |
| ▸ | MEN1 | O00255 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | EYA3 | Q99504 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | TTR | P02766 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29856228 | 0.81 | ADORA3 (0.46) | CYP2C19ALDH1A1HPGDGAAHSD17B10 | |
| SCHEMBL1288011 | 0.79 | SRC (0.55) | CYP2C19ALDH1A1HPGDGAAHSD17B10 | |
| SCHEMBL11558589 | 0.78 | ALDH1A1 (0.47) | CYP2C19ALDH1A1HPGDGAAHSD17B10 | |
| SCHEMBL984736 | 0.75 | EGFR (0.65) | CYP2C19ALDH1A1HPGDGAAHSD17B10 | |
| SCHEMBL30443220 | 0.75 | EGFR (0.65) | CYP2C19ALDH1A1HPGDGAAHSD17B10 | |
| SCHEMBL7278316 | 0.75 | EGFR (0.65) | CYP2C19ALDH1A1HPGDGAAHSD17B10 | |
| SCHEMBL29414698 | 0.73 | EGFR (0.66) | CYP2C19ALDH1A1HPGDGAAHSD17B10 | |
| SCHEMBL6671401 | 0.73 | EGFR (0.66) | CYP2C19ALDH1A1HPGDGAAHSD17B10 | |
| SCHEMBL9959370 | 0.73 | KMT2A (0.56) | CYP2C19ALDH1A1HPGDGAAHSD17B10 | |
| SCHEMBL1287917 | 0.72 | CNR1 (0.60) | CYP2C19MAPTCYP2C9SRCCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005750-B2 | Developing potent urate transporter inhibitors: compounds designed for their uricosuric action | J-PHARMA CO., LTD. (JP) | 2018-06-26 | — | — | US | disclosed |
| US-20130225673-A1 | DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION | J-PHARMA CO., LTD. (JP) | 2013-08-29 | — | — | US | disclosed |
| WO-2012048058-A2 | DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION | J-PHARMA CO., LTD. (JP) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005750-B2 | Developing potent urate transporter inhibitors: compounds designed for their uricosuric action | SLCO2B1, SLCO2A1, SLC10A6 | CYP2C19 269/4885ALDH1A1 1289/4885HPGD 1132/4885 |
| US-20130225673-A1 | DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION | SLCO2B1, SLCO2A1, SLC10A6 | CYP2C19 269/4885ALDH1A1 1289/4885HPGD 1132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.